Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “TIDES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 523 records · Page 29Linked to original sources
PubMed1965

[TIME AND TIDE].

Explore the source record for details and available documents.

Economics, Dental↗
PubMed2003

[Effects of marine bacteria on the growth and toxin production of red-tide algae under different pH and salinities].

The effects of strain S10 isolated from sediments of Xiamen Western Sea Area on the growth and paralytic shellfish poison (PSP) production of Alexandrium tamarense at different pH and salinities were studied. The results showed that the alga grew well at pH 6-8 and at salinity of 20-34. The toxicity of A. tamarense varied markedly at different pH and salinities: it decreased with increasing pH, while increased with salinity and reached its peak value at the salinity of 30, and then declined. The strain S10 inhibited the growth and the PSP production of A. tamarense at different pH and salinities. It had the best inhibitory function on the growth of A. tamarense at pH 7 and salinity of 34. The best inhibitory function on the PSP production of A. tamarense was at pH 7, but this inhibitory function was not related to salinity.

Bacteria↗
PubMed2003

[Advances in researches of aquatic ectoenzyme and its relationship with red tide].

Ectoenzymes play an important role in the material cycle and energy conversion in aquatic ecosystem. The researches of ectoenzyme are of significance in further understanding the marine carbon biogeochemical cycle and the countermeasures of algae under bloom conditions. In this paper, the research methods, characteristic activity and size distribution, controlling factors and their ecological significances of algal ectoenzymes were reviewed, and ectoenzyme introduced as one kind of new trophic state index.

Ecosystem↗
PubMed2003

[Several patients with a metastasised gastrointestinal stroma-cell tumor for whom the tide turned by the introduction of imatinib].

The introduction of imatinib for gastrointestinal stroma-cell tumours (GISTs) reversed the chances of 3 cancer patients who had given up hope. One 40-year-old man with multiple chemotherapy-resistant GIST responded well to imatinib treatment in a phase-I setting. Another patient, a woman aged 77 years, was initially considered too old for chemotherapy, but was later accepted for treatment in an imatinib phase-III trial due to the positive results in other patients. The last patient, a woman aged 48 years, also responded to treatment with imatinib despite a massive tumour load and a WHO performance status of 3. She was almost free of complaints within a period of just a few weeks. Until recently, the prognosis for metastatic or irresectable GIST was almost certain death within 1 year after diagnosis. The recent registration of imatinib has dramatically changed the prognosis of this disease. These case reports also demonstrate that some patients in phase-I studies can actually benefit from participation in such trials. Furthermore, treating GIST patients in a poor condition with imatinib is justified by the high response rates and mild toxicity.

Adult↗